All In Biotech

Drug Trial Radar · NCT03150056

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)

Last checked: Nov 19, 2026Latest source record: Aug 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

73

Actual

Start

Jul 18, 2017

Primary completion

Jul 31, 2020

Study completion Jun 22, 2021

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 11, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the combination of GSK525762 with other agents that have been shown to be effective in the treatment of CRPC or metastatic (m)CRPC. This study is designed to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on safety, tolerability, pharmacokinetic, and efficacy profiles of GSK525762 in combination with either abiraterone (Arm A) or enzalutamide (Arm B).

Conditions

  • Solid Tumours

Interventions

  • GSK525762Drug

    GSK525762 will be administered.

  • AbirateroneDrug

    Abiraterone will be administered.

  • EnzalutamideDrug

    Enzalutamide will be administered.

  • PrednisoneDrug

    Prednisone will be administered as a concomitant medication in combination with abiraterone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 21.3 months
  2. Number of Participants With AEs Leading to Any Dose Reduction or DelaysTime frame: Up to 21.3 months
  3. Number of Participants Who Withdrew Due to Toxicity and Changes in Safety AssessmentTime frame: Up to 21.3 months
  4. Percentage of Participants With Greater Than or Equals to (>=)50 Percent (%) Decrease in Prostate-specific Antigen From Baseline (PSA50)Time frame: Up to 21.3 months

Locations

20 sites in 4 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Towson, Maryland

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Detroit, Michigan

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Madison, Wisconsin

  • GSK Investigational Site

    Sydney, New South Wales, Australia

  • GSK Investigational Site

    Clayton, Victoria, Australia

  • GSK Investigational Site

    Melbourne, Victoria, Australia

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Málaga, Spain

  • GSK Investigational Site

    Sabadell (Barcelona), Spain

  • GSK Investigational Site

    Santander, Spain

  • GSK Investigational Site

    Glasgow, United Kingdom

  • GSK Investigational Site

    Sutton, London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.